{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:08:58Z","timestamp":1784819338994,"version":"3.55.0"},"reference-count":14,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T00:00:00Z","timestamp":1700352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cefepime is a fourth-generation cephalosporin and is a workhorse for the empiric treatment of febrile neutropenia (FN). Beta-lactam therapeutic drug monitoring (TDM) has emerged as a dose optimization strategy in patient populations with altered kinetics. Prior literature has demonstrated that patients with FN exhibit augmented renal clearance which may lead to subtherapeutic drug concentrations with standard dosing regimens. The aim of this study was to evaluate pharmacokinetic\/pharmacodynamic (PK\/PD) target attainment and clinical outcomes in patients with hematologic malignancies and FN who were treated empirically with cefepime.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a prospective, single-center study of adults with hematologic malignancies and FN admitted to the inpatient unit. The primary outcome was PK\/PD target attainment (defined as 100% free time greater than minimum inhibitory concentration (100% fT\u2009&gt;\u2009MIC)). Secondary clinical outcomes were time to defervescence, time to ANC recovery, in-hospital mortality, and cefepime failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 55 patients in our study. Forty-three (78%) patients achieved the primary outcome of PK\/PD target attainment. The mean time to defervescence was similar between those that achieved PK\/PD target attainment and those that did not (95% CI \u22120.75 to 1.25, p\u2009=\u20090.62).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study showed that standard cefepime dosing in patients with hematologic malignancies and FN does not result in achievement of 100% fT\u2009&gt;\u2009MIC in all patients. Patients in the group that did not achieve PK\/PD target attainment were younger with increased creatinine clearance, indicating that cefepime TDM may be especially beneficial in these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552231213883","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T02:34:26Z","timestamp":1700447666000},"page":"1207-1213","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Utilization of cefepime therapeutic drug monitoring in febrile neutropenia patients with hematologic malignancies"],"prefix":"10.1177","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3181-3488","authenticated-orcid":false,"given":"Emma F","family":"Lodl","sequence":"first","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad H","family":"Alshaer","sequence":"additional","affiliation":[{"name":"University of Florida College of Pharmacy, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Brooke","family":"Adams","sequence":"additional","affiliation":[{"name":"UF Health Shands Hospital, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Richards","sequence":"additional","affiliation":[{"name":"UF Health Shands Hospital, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Peloquin","sequence":"additional","affiliation":[{"name":"University of Florida College of Pharmacy, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena","family":"Venugopalan","sequence":"additional","affiliation":[{"name":"University of Florida College of Pharmacy, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,11,19]]},"reference":[{"key":"bibr1-10781552231213883","volume":"4","author":"Freifeld AG","year":"2011","journal-title":"Clin Infect Dis"},{"key":"bibr2-10781552231213883","unstructured":"National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections. Version 1.2021. http:\/\/www.nccn.org (accessed 11 April 2022)."},{"key":"bibr3-10781552231213883","volume-title":"Package insert","author":"Cefepime","year":"2009"},{"key":"bibr4-10781552231213883","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa359"},{"key":"bibr5-10781552231213883","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1807"},{"key":"bibr6-10781552231213883","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00389-15"},{"key":"bibr7-10781552231213883","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.04.008"},{"key":"bibr8-10781552231213883","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics1005050433946665"},{"key":"bibr9-10781552231213883","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-019-2378-9"},{"key":"bibr10-10781552231213883","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-015-4188-0"},{"key":"bibr11-10781552231213883","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-020-04096-z"},{"key":"bibr12-10781552231213883","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-273"},{"key":"bibr13-10781552231213883","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1692-y"},{"key":"bibr14-10781552231213883","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04323-0"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231213883","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552231213883","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231213883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:29:13Z","timestamp":1777688953000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552231213883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,19]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1177\/10781552231213883"],"URL":"https:\/\/doi.org\/10.1177\/10781552231213883","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,19]]}}}